GSK Looks To Cross PD-1 Gap And Leap To Next-Generation IO Backbone
This article was originally published in Scrip
GlaxoSmithKline PLC isn't letting the fact that it doesn’t have a PD-1/L1 inhibitor get its immuno-oncology R&D efforts down. Instead, the company is focusing immuno-oncology research on next-generation checkpoint modulators, including the OX40 agonist antibody GSK3174998 and first-in-class ICOS agonist antibody GSK3359609, the company said during an R&D day in New York City Nov. 3.
You may also be interested in...
GlaxoSmithKline's new CEO is assembling a "dream team" to rebuild the big pharma's R&D pipeline with an emphasis on building in oncology. Walmsley outlined her strategy at J.P. Morgan, while Oncology Therapy Area Head Axel Hoos provided more details in an interview.
Pfizer has reached a deal to buy Global Blood Therapeutics for $5.4bn, gaining the sickle cell therapy Oxbryta and building on efforts to reach underserved patient groups.
US drug pricing legislation that has picked up momentum could stymie R&D investment and curb the revenue tail for some big drugs, industry says, but CEOs also expect they can navigate the challenge.